Nora Khaldi is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics, and her years of research have focused primarily on protein evolution and comparative genomics. Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms. In 2014, she founded Nuritas, a Dublin-based biotech company that counts U2’s Bono and The Edge among its investors. Nuritas has c...
All content for From Lab to Launch by Qualio is the property of Qualio and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Nora Khaldi is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics, and her years of research have focused primarily on protein evolution and comparative genomics. Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms. In 2014, she founded Nuritas, a Dublin-based biotech company that counts U2’s Bono and The Edge among its investors. Nuritas has c...
Developing the undevelopable with Dave Miller, Chief Science Officer at AustinPx
From Lab to Launch by Qualio
44 minutes
6 months ago
Developing the undevelopable with Dave Miller, Chief Science Officer at AustinPx
As complexity in pharmaceutical development reaches new heights — especially with over 60% of recent FDA novel molecular entities falling outside traditional drug design rules — the need for advanced formulation and manufacturing strategies has never been greater. Precision medicine is no longer a future goal; it’s a present necessity. And that’s exactly where AustinPx comes in. At the forefront of this shift is AustinPx’s KinetiSol technology, a powerful platform designed to make the “undeve...
From Lab to Launch by Qualio
Nora Khaldi is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics, and her years of research have focused primarily on protein evolution and comparative genomics. Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms. In 2014, she founded Nuritas, a Dublin-based biotech company that counts U2’s Bono and The Edge among its investors. Nuritas has c...
